Entries by michelle hall

CoreRx, Inc. Announces Commercial Supply Agreement for Aimmune Therapeutics’ Investigational Peanut Allergy Treatment

Clearwater, Florida, May 14, 2019 — CoreRx, Inc. today announced that it has executed a commercial supply agreement with Aimmune Therapeutics, Inc., for the commercial manufacture of AR101, an investigational treatment for peanut allergy currently under review for potential approval by the U.S. Food and Drug Administration. CoreRx has been the development manufacturer of AR101 […]

CoreRx, Inc. announces that its client Bionpharma has received FDA approval for a generic version of ONFI® (Clobazam)

Clearwater, Florida- November 4, 2018 – CoreRx, Inc. announces that its client Bionpharma has received FDA approval for a generic version of ONFI® (Clobazam) Oral Suspension, 2.5mg/mL.  Clobazam Oral Suspension is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.  CoreRx developed the formulation […]

Installation of the Optel Line Master Serialization and Aggregation

Clearwater, Florida – As part of CoreRx, Inc’s growth in expanding its cGMP manufacturing capabilities to support niche commercial products, we are pleased to announce the completed installation of the Optel Line Master Serialization and Aggregation System for support of commercial liquid dosage form manufacturing.  In addition to handling serialization, which the FDA has mandated for commercial […]

Bionpharma Signs Drug Product Manufacturing Contract with CoreRx

Bionpharma Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Manufacture Generic Pharmaceuticals PRINCETON, NJ and Tampa, FL – July 30, 2018. Bionpharma, a global biopharmaceutical company, is pleased to report the Company has signed a Definitive Agreement with CoreRx, a leading Contract Development Manufacturing Organization (CDMO), for the development and manufacturing of a […]

Contract with Innovation Pharmaceuticals to formulate Sachets

Innovation Pharmaceuticals Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Package Brilacidin for Oral Mucositis in Sachet Form Brilacidin BEVERLY, MA – July 17, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a Drug Product manufacturing contract with CoreRx, a leading Contract […]

CoreRx, Inc. announces that its client Bionpharma Inc. has received FDA approval for a generic version of Banzel® (Rufinamide) Oral Suspension

Clearwater, Florida- June 3, 2018 – CoreRx, Inc. announces that its client Bionpharma Inc. has received FDA approval for a generic version of Banzel® (Rufinamide) Oral Suspension, 40mg/mL. Rufinamide Oral Suspension is a second in a series of products developed and manufactured by CoreRx to be approved for Bionpharma. Rufinamide is indicated for the adjunctive treatment […]